The University of Texas MD Anderson Cancer Center has entered into a strategic five-year partnership with Myriad Genetics, Inc. to advance the clinical evaluation and further development of Myriad's molecular residual disease (MRD) assay. This collaboration aims to assess the potential of the highly sensitive Precise MRD tests in enhancing treatment approaches for healthcare providers and improving patient outcomes.
As part of this initiative, both parties will conduct retrospective and prospective studies to examine the utility of these tests in cancers, including breast, gastrointestinal, genitourinary, and gynecological.
Currently, shares of Myriad Genetics are trading at C$0.43 on the Canadian Sec-Free Realtime, reflecting a 7.5 percent increase.
